Compare Fresenius Kabi Onco. with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NATCO PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NATCO PHARMA FRESENIUS KABI ONCO./
NATCO PHARMA
 
P/E (TTM) x 22.1 35.8 61.9% View Chart
P/BV x 3.1 5.1 61.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   NATCO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA
Mar-19
FRESENIUS KABI ONCO./
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs176849 20.7%   
Low Rs79557 14.1%   
Sales per share (Unadj.) Rs37.7573.8 6.6%  
Earnings per share (Unadj.) Rs5.1176.0 2.9%  
Cash flow per share (Unadj.) Rs6.7198.2 3.4%  
Dividends per share (Unadj.) Rs06.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs42.5842.7 5.0%  
Shares outstanding (eoy) m158.2336.50 433.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.41.2 275.6%   
Avg P/E ratio x25.04.0 625.5%  
P/CF ratio (eoy) x18.93.5 533.6%  
Price / Book Value ratio x3.00.8 358.6%  
Dividend payout %03.6 0.0%   
Avg Mkt Cap Rs m20,13525,660 78.5%   
No. of employees `0001.25.0 23.2%   
Total wages/salary Rs m7033,559 19.8%   
Avg. sales/employee Rs Th5,176.24,225.3 122.5%   
Avg. wages/employee Rs Th610.4718.0 85.0%   
Avg. net profit/employee Rs Th699.61,295.9 54.0%   
INCOME DATA
Net Sales Rs m5,96320,945 28.5%  
Other income Rs m181,302 1.4%   
Total revenues Rs m5,98122,247 26.9%   
Gross profit Rs m1,4307,948 18.0%  
Depreciation Rs m258810 31.8%   
Interest Rs m-26193 -13.5%   
Profit before tax Rs m1,2168,247 14.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,823 18.8%   
Profit after tax Rs m8066,424 12.5%  
Gross profit margin %24.037.9 63.2%  
Effective tax rate %28.122.1 127.3%   
Net profit margin %13.530.7 44.1%  
BALANCE SHEET DATA
Current assets Rs m5,10223,472 21.7%   
Current liabilities Rs m2,3857,287 32.7%   
Net working cap to sales %45.677.3 58.9%  
Current ratio x2.13.2 66.4%  
Inventory Days Days15092 162.7%  
Debtors Days Days11388 128.4%  
Net fixed assets Rs m5,14818,648 27.6%   
Share capital Rs m158365 43.3%   
"Free" reserves Rs m6,55634,525 19.0%   
Net worth Rs m6,73230,760 21.9%   
Long term debt Rs m9520-   
Total assets Rs m10,38843,031 24.1%  
Interest coverage x-45.843.7 -104.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.5 117.9%   
Return on assets %7.515.4 48.8%  
Return on equity %12.020.9 57.3%  
Return on capital %14.627.4 53.2%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29811,536 45.9%   
Fx outflow Rs m1,7722,939 60.3%   
Net fx Rs m3,5258,597 41.0%   
CASH FLOW
From Operations Rs m1,2746,688 19.1%  
From Investments Rs m-1,204-6,122 19.7%  
From Financial Activity Rs m-196-509 38.5%  
Net Cashflow Rs m-12666 -191.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 1.5 5,510.2%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 9.6 16.6 57.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   42,599 25,395 167.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ABBOTT INDIA  JUBILANT PHARMOVA   ELDER PHARMA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS